Novartis, Blackstone Invest $250 Million to Launch Anthos Therapeutics
Novartis and Blackstone Life Sciences, a private investment firm, have launched Anthos Therapeutics, a new biopharmaceutical company focused on advancing targeted therapies for high-risk cardiovascular patients. The company will be based in Cambridge, Massachusetts.
Blackstone Life Sciences provided $250 million for Anthos and will control the development of the products. Novartis will retain a minority equity interest in Anthos.
As part of this launch, Novartis has licensed to Anthos MAA868, an anti-thrombotic therapy and antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway.
John Glasspool, a former leader of Novartis’ cardiovascular franchise with 30 years of experience in the biopharmaceutical industry, will join Anthos as CEO. Mr. Glasspool served as Global Head of Novartis’ Cardiovascular and Metabolic Diseases franchise. He was previously Head of Corporate Strategy and a member of the Executive Team at Baxalta that led its acquisition by Shire.
Founding members of Anthos’ Board of Directors include Blackstone Managing Director Paris Panayiotopoulos, former CEO of Ariad Pharmaceuticals, and Blackstone Principal Ari Brettman, MD. Jonathan Freeman, MBA, PhD, Blackstone Senior Advisor and Anthos co-founder, joins as Chief Business Officer.
Shaun Coughlin, MD, PhD, Novartis’ Global Head of Cardiovascular and Metabolism joins as an Observer to Anthos’ Board. Craig Basson, MD, PhD, Novartis’ Head of Cardiovascular and Metabolism Translational Medicine joins Anthos’ Scientific Advisory Board
Source: Anthos Therapeutics